Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Hudson on the Rise of Liquid Biopsies in Lung Cancer

January 30th 2020

Kathryn E. Hudson, MD, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.

Dr. Polsky on the Exploration of Blood-Based Biomarkers in Melanoma

January 30th 2020

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

Dr. Martin on Biomarker-Driven Therapeutics in Multiple Myeloma

January 29th 2020

Thomas G. Martin, MD, discusses biomarker-driven treatment options in multiple myeloma and currently available regimens.

Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in Osteosarcoma

January 29th 2020

Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.

Dr. Aboulafia on Targeted Therapy in Tenosynovial Giant Cell Tumor

January 29th 2020

Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

CMS Expands Coverage of NGS Diagnostic Tests for Germline Ovarian, Breast Cancers

January 29th 2020

The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.

Gene Signatures Predict for Radiation Response in Breast Cancer

January 28th 2020

Recent studies have demonstrated that somatic mutations of ATM denote greater response to radiation therapy and that gene patterns may help predict the timing of recurrence following radiation.

2019 ASH; Best Abstracts for CLL

January 28th 2020

CAR T-Cell Therapy for Relapsed/Refractory CLL

January 28th 2020

Sequencing Strategies for CLL

January 28th 2020

PI3 Kinase Inhibitors for Relapsed/Refractory CLL

January 28th 2020

Management of CLL Progression After Ibrutinib

January 28th 2020

Resistance to Therapy in CLL

January 28th 2020

Combinations for Relapsed or Refractory CLL

January 28th 2020

Fixed-Duration Therapy for Relapsed CLL

January 28th 2020

Health Maintenance in CLL

January 28th 2020

Distinguishing Features Among BTK Inhibitors

January 28th 2020

Combining Targeted Therapies in CLL

January 28th 2020

Ibrutinib + Venetoclax for CLL

January 28th 2020

Treatment for Younger Fit Patients With CLL

January 28th 2020